Gregory Alan Lazar

Title: Gregory Alan Lazar: A Pioneer in Antibody Innovations

Introduction:

In the field of biotechnology and medical research, Gregory Alan Lazar, based in Arcadia, CA, has emerged as a prominent inventor and patent holder. With an impressive 57 patents to his name, Lazar's contributions have greatly advanced the development of optimized antibodies for therapeutic applications. This article delves into his latest patents, notable companies he has worked for, and some of his accomplished coworkers.

Latest Patents:

Gregory Alan Lazar's recent patents highlight his expertise in the field of immunology and antibody engineering. One of his groundbreaking inventions includes "Optimized antibodies that target CD19." These antibodies possess specific modifications that enhance their affinity to an FcR or alter their effector function compared to the parent antibody. This innovation opens up new possibilities for improved therapeutic outcomes in diseases where CD19 is implicated.

Another noteworthy patent by Lazar is for "Methods and compositions for inhibiting CD32B expressing cells." This invention revolves around immunoglobulins that bind FcRIIb+ cells and coengage the antigen on the cell's surface, thereby inhibiting the activity of these cells. With this patent, Lazar has contributed to the development of potential therapies for conditions associated with CD32B expressing cells.

Companies Worked In:

Lazar's expertise has been sought after by renowned organizations in the biotechnology and pharmaceutical industries. Notably, he has made significant contributions during his tenure at Xencor, Inc. This California-based biotechnology company is focused on the discovery and development of engineered monoclonal antibody and protein therapeutics.

In addition, Lazar has also worked at CHUGAI SEIYAKU KABUSHIKI KAISHA, a leading Japanese pharmaceutical company. Chugai is known for its biotechnology-based approach to drug discovery, with a particular emphasis on oncology, renal and autoimmune diseases.

Accomplished Coworkers:

Throughout his career, Lazar has collaborated with talented individuals who share his passion for scientific advancements. Two notable coworkers include Sher Bahadur Karki and John Desjarlais. While specific details about their collaborative work are not provided, their shared expertise and contributions to the field undoubtedly complement Lazar's own achievements.

Conclusion:

Gregory Alan Lazar's contributions to the field of immunology and antibody engineering have propelled advancements in the development of optimized antibodies for therapeutic purposes. With an extensive portfolio of 57 patents, Lazar has made significant contributions to scientific research and innovation. His work at Xencor, Inc. and CHUGAI SEIYAKU KABUSHIKI KAISHA showcases his ability to thrive in renowned organizations dedicated to advancing pharmaceutical and biotechnology frontiers. Lazar's collaborations with accomplished coworkers further demonstrate the collective effort required for groundbreaking advancements in the field.